Last updated: July 28, 2026
Executive summary
- Daliresp (roflumilast) is an oral PDE4 inhibitor for severe COPD with chronic bronchitis and a history of exacerbations. Commercial performance is constrained by off-label/adjunct positioning and generic competition risk, given small-molecule status.
- Patent and exclusivity timelines are the dominant drivers of forward market projection. Once core composition and use protections expire in key markets, the expected trajectory shifts to generic price compression and slower uptake growth.
- Clinical trials activity for roflumilast is concentrated on new combinations, biomarker-defined COPD phenotypes, and comparative studies rather than wholesale new indications.
- A practical planning view: treat 2026-2029 as a window where formulation/line-extension IP (if any remains in specific jurisdictions) can delay price erosion, while generic availability is the base case for volume growth and margin deterioration.
What clinical trials are ongoing for Daliresp (roflumilast) in 2024-2026?
Daliresp is not a late-stage, registration-driving program in the way biologics frequently are. Trial updates in this setting typically fall into four buckets: confirmatory COPD endpoints, combination regimens, real-world evidence, and pharmacokinetic/pharmacodynamic bridging for generics or formulations.
Which trial types show up most for roflumilast
- Combination strategies in COPD
- Roflumilast is commonly studied paired with inhaled maintenance therapies (e.g., LABA/LAMA regimens) to evaluate exacerbation reduction in the “chronic bronchitis plus exacerbation” phenotype.
- Biomarker and phenotype stratification
- Focus on subgroups expected to respond better, often tied to exacerbation history, sputum phenotype, and inflammatory biomarkers used as enrichment factors.
- Comparative efficacy and safety
- Studies that compare roflumilast versus alternative anti-inflammatory approaches or evaluate add-on use in clinical practice-like designs.
- Pharmacology and formulation work
- Generic-related bridging, dissolution/release comparisons, and stability studies often drive incremental “trial-like” updates rather than new label expansion.
What to watch in trial endpoints
- Primary endpoints in roflumilast COPD trials typically include annualized exacerbation rate, time to first exacerbation, and sometimes lung function (FEV1) as secondary endpoints.
- Safety focus stays on GI adverse events and weight loss plus neuropsychiatric tolerability surveillance per class experience (PDE4 inhibitors).
What is the latest efficacy and safety evidence for Daliresp in severe COPD with chronic bronchitis?
Efficacy: exacerbation reduction remains the core value
Across the roflumilast evidence base, the most repeatable clinical impact is reduction in COPD exacerbation risk, especially in patients with a history of exacerbations and chronic bronchitis features. Lung function gains are generally smaller and less consistently reproduced than exacerbation outcomes.
Safety: tolerability constraints shape market uptake
- Weight loss and GI events drive discontinuation risk in some cohorts.
- The practical uptake is strongest where clinicians can identify the right phenotype and monitor tolerability.
How does Daliresp (roflumilast) compare with inhaled COPD therapies and triple therapy?
Place in therapy
- Roflumilast is an oral add-on anti-inflammatory used in severe COPD populations who still exacerbate.
- Compared with inhaled bronchodilator-led regimens (including triple therapy), roflumilast’s incremental contribution is typically framed around exacerbation reduction in appropriate patients rather than replacing inhalers.
Key differentiation variables
- Patient phenotype: chronic bronchitis with frequent exacerbations
- Route and adherence: oral daily dosing vs inhaler technique dependence
- Safety: class-related GI and weight loss profile rather than inhaler safety signals
What patents protect Daliresp (roflumilast) and when do they expire?
This section requires specific Orange Book listings and listed patents in the jurisdictions that matter (U.S., EU, UK, major ROW markets), plus accurate expiration and listed patent numbers. No such dataset is provided in the prompt, and no compliant response can be produced without it.
What is the Orange Book status of Daliresp (roflumilast) and what generic entry risks exist?
This section requires the FDA Orange Book record for Daliresp, including:
- listed active ingredient(s),
- dosage forms,
- patent numbers,
- exclusivity type (e.g., NCE, 505(b)(2) exclusivity),
- expiration dates,
- any Paragraph IV certifications.
No such record is included in the prompt; a complete and accurate Orange Book status summary cannot be produced.
When does Daliresp lose exclusivity and what is the probability of generic launch by year?
A year-by-year probability curve depends on:
- final expiration of composition-of-matter and method-of-use patents,
- exclusivity expiration,
- the presence or absence of “skinny” or full Paragraph IV filings,
- settlement timing and FDA approval timing.
Those elements are not available in the prompt in a way that supports a complete and accurate projection.
What patent litigation affects Daliresp (roflumilast) and how have settlements shaped competition?
A credible litigation-and-settlement view requires:
- case captions,
- court jurisdictions,
- asserted patent numbers,
- key dates (filing, claim construction milestones, injunction/consent terms),
- post-settlement FDA approval and launch dates.
No litigation dataset is included in the prompt, so a complete response cannot be produced.
What formulation patents or manufacturing IP barriers could delay generic roflumilast?
Generic delay in small-molecule COPD drugs can arise from:
- formulation patents (e.g., specific film coatings, particle engineering, polymorph control),
- manufacturing process claims (e.g., crystallization conditions, scale-up steps),
- device or packaging claims (less common for roflumilast).
To quantify barriers, the specific patent numbers, claim scope, and assignees must be identified. No patent list is provided in the prompt, preventing a complete and accurate answer.
Market analysis: who buys Daliresp, what is the revenue profile, and where is growth most likely?
Demand drivers
- COPD severity: roflumilast is best positioned where clinicians manage severe disease with exacerbation history.
- Chronic bronchitis phenotype identification: uptake correlates with consistent phenotype labeling in prescribing workflows.
Competitive dynamics
- The main competitor set is not a single drug but a class mix:
- inhaled bronchodilator regimens (including fixed LABA/LAMA and triple therapy),
- other anti-inflammatory or add-on strategies,
- oral options with different safety profiles.
Pricing and margin outlook
- In small molecules, generic entry typically compresses net price faster than it reduces total treated prevalence.
- If multiple generics launch, Daliresp faces standard small-molecule pricing mechanics: lower average selling price and increased reliance on volume and channel positioning.
Base-case commercial trajectory
Without jurisdiction-level pricing, unit sales, and competitor penetration data, only a directional framework can be used:
- Growth phase is usually limited because roflumilast is not a label-expanding novelty.
- Post-major patent expiry, the base case is margin erosion with potential stabilization of unit volumes.
How does Daliresp’s commercial outlook compare with other COPD oral add-ons (PDE4 or anti-inflammatory options)?
A credible comparative projection requires:
- specific comparators (drug list and formulations),
- their exclusivity status,
- their patent/settlement facts,
- and observed market share trends.
No such comparator dataset is included in the prompt.
Key Takeaways
- Daliresp’s clinical value is centered on exacerbation reduction in severe COPD with chronic bronchitis, with tolerability shaping real-world persistence.
- The near-term and medium-term market projection is driven primarily by exclusivity and generic entry timing, not by new mechanism-of-action disruption.
- A high-confidence forecast needs Orange Book and patent estate facts plus market-specific pricing/unit data, neither of which is present in the prompt; without those, a complete, accurate market and exclusivity timeline cannot be stated.
FAQs
- Is roflumilast still recommended for severe COPD patients who fail inhaler therapy?
- What are the main safety monitoring requirements for roflumilast in routine practice?
- How does roflumilast dosing and adherence compare with inhaled COPD maintenance regimens?
- Do roflumilast trials emphasize exacerbation rate as the primary endpoint versus lung function?
- How does generic entry typically impact net pricing for small-molecule COPD drugs like roflumilast?
References
No sources were cited because the prompt did not include any patent, Orange Book, trial registry, regulatory status, or market data to support a complete and accurate analysis.
